Enterprise Value

10.14M

Cash

1.421M

Avg Qtr Burn

-6.224M

Short % of Float

0.91%

Insider Ownership

28.19%

Institutional Own.

40.60%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Ameluz (aminolevulinic acid hydrochloride) Details
BCC (basal cell carcinoma), AK (actinic keratosis)

Approved

Quarterly sales

PDUFA

Approval decision

Ameluz® Details
Actinic keratosis

Phase 3

Data readout

Phase 2

Data readout